We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bone Marrow Donors May Transfer Pathogenic Mutations to Patients

By LabMedica International staff writers
Posted on 27 Jan 2020
Clonal hematopoiesis of indeterminate potential, or CHIP, is characterized by the presence of mutant hematopoietic stem cell clones in the bone marrow without overt signs of disease.

However, emerging evidence suggests that this CHIP condition, which is more common in older patients, may not be as innocuous as previously thought, with recent studies connecting CHIP to a variety of medical problems.

A team of hematology and oncology experts led by the Washington University School of Medicine (St. More...
Louis, MO, USA) demonstrated in a new sequencing study that even young bone marrow donors may have pathogenic mutations that can take hold in those receiving stem cell transplants for acute myeloid leukemia (AML) or other blood cancers. They used deep, error-corrected sequencing, a method designed to detect mutations at levels as low as one in 10,000 cells, to search for somatic mutations in 80 AML-related genes in multiple bone marrow and blood samples from 25 matched bone marrow donors and recipients.

In the process, the team tracked down somatic mutations in 11 of the donors between the ages of 20 and 58 years. The vast majority of those mutations were predicted to be pathogenic, and all of those risk mutations subsequently turned up in corresponding bone marrow samples from stem cell transplant recipients. Clonal mutations, with a median variant allele frequency of 0.00247, were found in 11 donors (44%; median, 36 years old). Of the mutated clones, 84.2% of mutations were predicted to be molecularly pathogenic and 100% engrafted in recipients.

Perhaps most concerning, the team noted that graft-versus-host disease eventually occurred in three quarters of the AML patients who received mutation-containing bone marrow and had those mutations in their own marrow later on. In contrast, graft-versus-host disease turned up in around half of the patients who received seemingly mutation-free bone marrow.

Todd Druley, MD, PhD, an associate professor of pediatrics and senior author of the study, said, “We didn't expect this many young, healthy donors to have these types of mutations. We also didn't expect 100% of the harmful mutations to be engrafted into the recipients. That was striking. This study raises concerns that even young, healthy donors' blood stem cells may have harmful mutations and provides strong evidence that we need to explore the potential effects of these mutations further.” The study was published on January 15, 2020 in the journal Science Translational Medicine.

Related Links:
Washington University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.